PMID- 18704666
OWN - NLM
STAT- MEDLINE
DCOM- 20090903
LR  - 20211020
IS  - 0145-479X (Print)
IS  - 0145-479X (Linking)
VI  - 40
IP  - 3
DP  - 2008 Jun
TI  - Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological 
      targets for anti-cancer agents.
PG  - 213-7
LID - 10.1007/s10863-008-9158-6 [doi]
AB  - Recently, it was demonstrated that some anti-cancer agents used mitochondrial 
      voltage-dependent anion channels (VDAC1-3 isoforms) as their pharmacological 
      target. VDACs are expressed more highly in cancer cells than normal cells; thus 
      the VDAC-dependent cytotoxic agents can have cancer-selectivity. 
      Furanonaphthoquinones (FNQs) induced caspase-dependent apoptosis via the 
      production of NADH-dependent reactive oxygen species (ROS) by VDAC1. The ROS 
      production and the anti-cancer activity of FNQs were increased by VDAC1 
      overexpression. Meanwhile, erastin induced RAS-RAF-MEK-dependent non-apoptotic 
      cell death via VDAC2. On the other hand, VDACs were needed for transporting ATP 
      to hexokinase (HK), which was highly expressed in cancer cells. We hypothesized 
      that the high glycolysis might induce up-regulation of VDAC. In this review, we 
      propose that VDACs are novel candidates for effective pharmacological targets of 
      anti-cancer drugs.
FAU - Simamura, Eriko
AU  - Simamura E
AD  - Department of Molecular and Cell Structural Science, Kanazawa Medical University, 
      Ishikawa, Uchinada, Japan. simamura@kanazawa-med.ac.jp
FAU - Shimada, Hiroki
AU  - Shimada H
FAU - Hatta, Toshihisa
AU  - Hatta T
FAU - Hirai, Kei-Ichi
AU  - Hirai K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Bioenerg Biomembr
JT  - Journal of bioenergetics and biomembranes
JID - 7701859
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Mitochondrial Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Piperazines)
RN  - 0 (Protein Isoforms)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Voltage-Dependent Anion Channels)
RN  - 0 (erastin)
RN  - EC 2.7.11.1 (raf Kinases)
RN  - EC 3.6.5.2 (Oncogene Protein p21(ras))
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacokinetics/therapeutic use
MH  - Apoptosis/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Glycolysis/drug effects
MH  - Humans
MH  - Mitochondrial Proteins/*antagonists & inhibitors/metabolism
MH  - Neoplasm Proteins/*antagonists & inhibitors/metabolism
MH  - Neoplasms/*drug therapy/metabolism
MH  - Oncogene Protein p21(ras)/metabolism
MH  - Piperazines/pharmacokinetics/therapeutic use
MH  - Protein Isoforms/antagonists & inhibitors/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Voltage-Dependent Anion Channels/*antagonists & inhibitors/metabolism
MH  - raf Kinases/metabolism
RF  - 29
EDAT- 2008/08/16 09:00
MHDA- 2009/09/04 06:00
CRDT- 2008/08/16 09:00
PHST- 2008/08/16 09:00 [pubmed]
PHST- 2009/09/04 06:00 [medline]
PHST- 2008/08/16 09:00 [entrez]
AID - 10.1007/s10863-008-9158-6 [doi]
PST - ppublish
SO  - J Bioenerg Biomembr. 2008 Jun;40(3):213-7. doi: 10.1007/s10863-008-9158-6.